Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016’, provides an overview of the Genital Warts (Condylomata Acuminata) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Warts (Condylomata Acuminata), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)

The report reviews pipeline therapeutics for Genital Warts (Condylomata Acuminata) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Genital Warts (Condylomata Acuminata) therapeutics and enlists all their major and minor projects

The report assesses Genital Warts (Condylomata Acuminata) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Genital Warts (Condylomata Acuminata)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Agilvax, Inc.

Aviragen Therapeutics, Inc.

Biogenomics Limited

BioMAS Ltd.

Cutanea Life Sciences Inc

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Laboratories Ojer Pharma S.L. ...

Agilvax, Inc.

Aviragen Therapeutics, Inc.

Biogenomics Limited

BioMAS Ltd.

Cutanea Life Sciences Inc

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Laboratories Ojer Pharma S.L.

LEO Pharma A/S

Novan, Inc.

Novartis AG

Tamir Biotechnology, Inc.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Genital Warts ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Genital Warts (Condylomata Acuminata) Overview 7

Therapeutics Development 8

Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview 8

Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies 9

Genital Warts (Condylomata Acuminata) - Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Genital Warts (Condylomata Acuminata) - Products under Development by Companies 12

Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development 13

Agilvax, Inc. 13

Aviragen Therapeutics, Inc. 14

Biogenomics Limited 15

BioMAS Ltd. 16

Cutanea Life Sciences Inc 17

Foamix Pharmaceuticals Ltd. 18

G&E Herbal Biotechnology Co., Ltd. 19

Laboratories Ojer Pharma S.L. 20

LEO Pharma A/S 21

Novan, Inc. 22

Novartis AG 23

Tamir Biotechnology, Inc. 24

Zydus Cadila Healthcare Limited 25

Genital Warts (Condylomata Acuminata) - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

AX-03 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

BTA-074 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CB-0602 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

human papillomavirus vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

imiquimod - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

imiquimod SR - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ingenol mebutate - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

interferon alfa-2b - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

LFX-453 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

omiganan pentahydrochloride - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

PP-210 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

ranpirnase - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

SB-206 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

SRT-100 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Genital Warts (Condylomata Acuminata) - Dormant Projects 58

Genital Warts (Condylomata Acuminata) - Discontinued Products 59

Genital Warts (Condylomata Acuminata) - Product Development Milestones 60

Featured News & Press Releases 60

May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206 60

May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016 8

Number of Products under Development by Companies, H2 2016 ...

List of Tables

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H2 2016 13

Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H2 2016 14

Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H2 2016 15

Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H2 2016 16

Genital Warts (Condylomata Acuminata) - Pipeline by Cutanea Life Sciences Inc, H2 2016 17

Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 18

Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 19

Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H2 2016 20

Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H2 2016 21

Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H2 2016 22

Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H2 2016 23

Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H2 2016 24

Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Genital Warts (Condylomata Acuminata) - Dormant Projects, H2 2016 58

Genital Warts (Condylomata Acuminata) - Discontinued Products, H2 2016 59

List of Figures

List of Figures

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016 8

Number of Products under Development by Companies, H2 2016 ...

List of Figures

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Top 10 Targets, H2 2016 27

Number of Products by Stage and Top 10 Targets, H2 2016 27

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Molecule Types, H2 2016 33

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports